Conference Programme

Wednesday 3 July 2019

08:30

Registration opens

09:00-10:30

MS&R Committee meeting

09:00-11:00

Refreshments + exhibition + networking

11:00-13:00

Hyperlipidaemia Education Study Day:         

Organised by:   Handrean SORAN
Co-chairs: Handrean SORAN + Jan HO

Practitioners Guide to Behaviour Change?

Organised by:   Michaela NUTTALL
Co-chairs: Ms Alison Pottle + Ms Suzanne Watkins

 

Invitation to:  

Scientists • PhD students • Consultants • SpR’s working within clinical chemistry, endocrine and diabetes •  Cardiology consultants and trainees • Specialist nurses,  • Those involved in the field of lipidology and cardiovascular risk.

Invitation to:

Dietitians, Doctors, Nurses and Nutritionists across both primary and secondary care

 

11:00 - 11:20
The role of glucose lowering in preventing cardiovascular disease: should we change practice?

While glucose-lowering per se in preventing cardiovascular disease has been a subject of controversy recent clinical trials of novel medications  for type 2 diabetes have ushered in a new era of cardioprotection that extends beyond glucose control.

 

Prof Andrew KRENTZ

Visiting Professor of Medical Science
University of Reading, Institute for Cardiovascular & Metabolic Research, Reading, UK

 

11:30-11:50

Use of LDL and  non-HDLcholesterol and apolipoproteins B and (a)

 

Prof Paul DURRINGTON

Professor of Medicine
Cardiovascular Research Group, University of Manchester, Manchester, UK

 

12:20-12:20

Nutraceuticals: their role in treating hyperlipidaemia in the world of evidence based medicine

Beneficial effects on plasma lipids are claimed for many nutraceuticals and functional foods, this presentation will review the efficacy of preparations supported by high-quality clinical evidence.

 

Dr Peter PENSON

Senior Lecturer in Pharmacology and Pharmacy Practice
Liverpool John Moores University, Liverpool, UK

 

 

12:30-12:50

Hypertension: managing hypertension: How low to go, evidence based practice and an update on guidelines

 

Prof Tony HEAGERTY

Head of the School of Medical Sciences and Professor of Medicine

Division of Cardiovascular Sciences, University of Manchester, UK

 

11:05-11:45

Positive psychology ‘in a nutshell’. All you need to know to motivate your patients for change- in ten minute appointments!
So many modern diseases result from lifestyle choices around diet and exercise. How can busy clinicians help their patients make better informed, more goal focused choices.


Dr David UNWIN

GP, Norwood Surgery in Southport

 

Dr Jen UNWIN
Consultant Clinical Health Psychologist

 

11:45-12:25

Triglycerides- why are raised levels so common and what is the link with Type 2 diabetes? Can anything be done in Primary care reverse these twin epidemics?

20% of our patients have fatty liver and or a high triglyceride level Why is this so common and is it important? I look at a pragmatic approach for primary care which can deliver 30% improvements in triglyceride levels & 40% type 2 diabetes remission- without drugs.


Dr David UNWIN

GP, Norwood Surgery in Southport

 

12:25-12:50

Examples of good practice

Ms Alison Pottle and Ms Suzanne Watkins  

 

12:50-13:00
Discussion 

13:00-14:00

Lunch + exhibition + networking 

14:00-14:40

Reducing the CVD risk in people with diabetes: Current nutrition guidelines from Diabetes UK

Discussing the evidence for role of foods in reducing CVD risk in people with diabetes:

 How to we interpret the evidence?

What are the important nuances?

And what are the practicalities of the recommendations?

 

Mr Douglas TWENEFOUR
Deputy Head of Care,Diabetes UK, London, UK 

14:40-15:00

Comfort break 

15:00-15:50

SPONSORED SYMPOSIUM 1:     

Changing the Face of Homozygous Familial Hypercholesterolaemia (HoFH)

   

 

15:00   

Chair’s Welcome: The Unmet Need in HoFH        
Dr Dev DATTA

 

15:05 

Advances in HoFH Management 

Dr Handrean SORANMiss Kirsty NICHOLSON

 

15:20   

The HoFH Journey – a Patient’s Perspective      

Mrs Cindy Evans

 

15:35   

Panel Q & A    

 

15:50   

Summary & Close                                                      

Dr Dev DATTA

 

16:00-17:20

COMBINED SPONSORED SYMPOSIUM 2:

Cholesterol Management: Doing more for cardiovascular patients in the new NHS

 

 

                      

 

Symposium Chair: Dr Nigel CAPPS

 

16:05 - 16:25

The NHS Long Term Plan; what will it mean for CVD prevention?

Mr Steve GRANGE

Executive Director of Strategy and Business Development, Midlands Partnership NHS Foundation Trust (previously SSSFT)

 

16:25 - 16:45

The Accelerated Access Collaborative's (ACC) role in supporting proven, cost-saving innovative innovations

Dr Keri TORNEY

Deputy Director of Life Sciences, NHS England and NHS Improvment

 

16:45 - 17:15

The Evolving NHS and role for Lipidologists in CVD and cholesterol management

Panel Discussion:

Dr Graham BAYLY, University Hospitals Bristol

Dr Dev DATTA, Cardiff and Vale UHB

Dr Pankaj GUPTA, University Hospitals of Leicester

 

This promotional meeting has been jointly organised and funded by Amgen and Sanofi.

18:15-18:45

HEART UK AGM (members only)

19:00-22:00

Welcome buffet reception

Thursday 4 July 2019

08:00

Registration opens

08:00-09:00

Lipid Interest group committee meeting
Host:
Alison POTTLE

08:00-09:00

Moderated and Unmoderated poster session 

 

Judging panel:
Elizabeth HUGHES, Alan REESMaggie WILLIAMS 

 

1/

FAMILIAL HYERCHOLESTEROLAEMIA SERVICE –A SYNOPSIS FROM GLOUCESTERSHIRE LIPID CLINICS
A.Hamlen1, M.Balasubramani2 and K.S. Gan2
1 Department of Diabetes and Endocrinology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK
2 Department of Chemical Pathology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK

2/
THREE YEARS EXPERIENCE OF LOMITAPIDE THERAPY IN THE UK
Cegla J
, Walji S, Neuwirth C, Barton L, Thompson G, Scott J

Hammersmith Hospital Lipid Clinic, Imperial College Healthcare NHS Trust 

 

3/
EVOLOCUMAB THERAPY AND A POSSIBLE ASSOCIATION WITH SKIN REACTIONS
 
A. Ragavan1, A. David1, J. Scott1, S. Walji1, J. Cegla1*

1Hammersmith Hospital Lipid Clinic, Imperial College Healthcare NHS trust, London, United Kingdom 

 

4/
SCREENING FOR LALD IN LIPID CLINICS

S Kwok 1,2, B Garside *1,2, S Rajbhandari 3, M Hough 4, J Smith 5, A Al-bahrani 6, A Basu 7, B Mishra 8, A Bickerton 9, H Soran 1,2.1 Lipoprotein Research Group, Faculty of Biology, Medicine & Health, University of Manchester2 Cardiovascular Trials Unit, Manchester University NHS Foundation Trust3 Lancashire Teaching Hospitals NHS Foundation Trust4 Royal Devon and Exeter NHS Foundation Trust5 The Dudley Group NHS Foundation Trust6 Isle of Wight NHS Trust7 Sandwell and West Birmingham Hospitals NHS Trust8 The Pennine Acute Hospitals NHS Trust9 Yeovil District Hospital NHS Foundation Trust 

 

5/
GENETIC TESTING FOR FAMILIAL HYPERCHOLESTEROLAEMIA, ARE WE TESTING THE RIGHT PATIENTS?
*Haslam S1, Salazar L2, Allcock R1
1
Clinical Biochemistry Department, Lancashire Teaching Hospitals NHS Trust
2Diabetes and Endocrinology Department, Lancashire Teaching Hospitals NHS Trust
 

 

6/
TEST PERFORMANCE OF GENETIC TESTING IN FAMILIAL HYPERCHOLESTEROLAEMI IN A LOCAL LIPID CLINIC
M.Mirzazadeh
1, M Kohli 2, G.Ferns3Epsom & St Helier University Hospitals NHS Trust1, Brighton & Sussex University Hospital NHS Trust2, Brighton & Sussex Medical School, Brighton3, UK

 

7/
LIPOPROTEIN (a) IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA
Dunn R1, Sutton P1, Desborough R1  and Narayanan D1.

1 Department of Chemical Pathology, Hull University Teaching Hospitals NHS Trust, Hull

 

8/
LIPOPROTEIN (a) AND CAROTID INTIMA MEDIA THICKNESS AS AN ADJUST TO CVD RISK ASSESSMENT IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA OR HIGH CARDIOVASCULAR RISK
R.N.K, Ranasinghe
1, R.P. Vincent1, R. Chandra1, N. Rao1
1
Department of Clinical Biochemistry, King’s College Hospital NHS Foundation Trust, Denamrk Hill, London, SE5 9RS 

 

9/
African ApoE2/3 diabetic patients seldom develop dyslipidaemia
Tanyanyiwa DM1,2*, Buthelezi PE3, Bhana SA4 and Dandara C5.

1. Department of Chemical Pathology, University of the Witwatersrand, Johannesburg, South Africa

2. Department of Chemical Pathology, Sefako Makgatho University, Pretoria, South Africa

3. Department of Health, Gauteng Region, Johannesburg South Africa 

4. Department of Medicine, University of University of the Witwatersrand, Johannesburg, South Africa.

5. Department of Human Genetics, University of University of the Cape Town, Johannesburg, South Africa.

 

10/

HOW DOES BURDEN OF ILLNESS OF FCS PATIENTS COMPARE TO A GENERAL POPULATION COHORT? RESULTS OF A PSM STUDY

Davidson1, A. Hsieh2, R. Jones2, N. Hadker3, S. Suarez3, M. Stevenson2

1. Department of Medicine, University of Chicago, Chicago, IL, US

2. Akcea Therapeutics, Boston, MA, USA

3. Trinity Partners, Waltham, MA, USA


UNmoderated Posters  

 

11/
LIPID CLINICS - A NEW ROLE FOR CLINICAL SCIENTISTS
Allcock R*, Salazar L, Haslam S

Department of Clinical Biochemistry, Lancashire Teaching Hospitals NHS Foundation Trust.
Royal Preston Hospital, Sharoe Green Lane, Fulwood, Preston, PR2 9HT.
 

 

12/
A RETROSPECTIVE OBSERVATIONAL STUDY TO DETERMINE BASELINE CHARACTERISTICS AND EARLY PRESCRIBING PATTERNS FOR PATIENTS RECEIVING ALIROCUMAB IN UK CLINICAL PRACTICE
T. Reynolds1, P. Carey2, J. George3, G. Konidaris4, D. Narayanan5, S. Ramachandran6, A. Viljoen7, G. Ferns*8

1. Queen’s Hospital, Burton-on-Trent, England

2. Sunderland Royal Hospital, Sunderland, England

3. Ninewells Hospital, Dundee, Scotland

4. Sanofi UK, Guilford, England

5. Hull and East Yorkshire Hospitals NHS Trust, Hull, England

6. Good Hope Hospital/Birmingham Heartlands Hospital, England

7. Lister Hospital, Stevenage, England

8 Brighton & Sussex University Hospital, Brighton, England

 

13/
POST-MENOPAUSAL WOMEN WITH TOTAL CHOLESTEROL (TC) >7.5MMOL/L AND A CT CORONARY CALCIUM AGATSTON SCORE OF 0.
SHOULD WE TREAT THESE PATIENTS WITH LOW DOSE STATIN OR WITH A STRICT LOW FAT DIET?
Hassanen G
*, Ashby H

Department of Biochemistry, Russells Hall Hospital, Dudley Group of Hospitals 

 

14/
‘REAL WORLD’ USE OF PCSK9 INHIBITORS IN LIPID CLINICS IN SE ENGLAND
N.Johri
1, J.Cabrera-Abreu2, C.Livingstone3, Y.Lolin4, M.Malik5, N.Maghsoodi6, M.Mirzazadeh1, N.Rao7, R.Salota1, A.Simhadri7, A.Tarn8, G.Ferns5.Epsom & St Helier University Hospitals NHS Trust1, Royal Berkshire Hospital NHS Trust2, Royal Surrey County Hospital NHS Trust3, East Sussex Healthcare NHS Trust4, Surrey & Sussex Healthcare NHS Trust6, Croydon Health Services NHS Trust8, King’s College Hospital NHS Foundation Trust7, Brighton & Sussex Medical School, Brighton5, UK. 

 

15/
APPLICATION OF THE THEORETICAL DOMAINS FRAMEWORK (TDF) IN THE DEVELOPMENT OF AN INTERVENTION TO OPTIMISE ADHERENCE TO LIFESTYLE TREATMENT RECOMMENDATIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA.
F.J. Kinnear
*1, E.Wainwright2, J. Bourne1, F.E., Lithander1, J.Hamilton-Shield1 and A.Searle1
1
NIHR Bristol Biomedical Research Centre (Nutrition theme), Bristol, U.K.
2.Psychology Department, Bath Spa University, Bath, U.K. 

 

16/
RISK FACTORS ASSOCIATED WITH STATIN ASSOCIATED MUSCLE SYMPTOMS IN PATIENTS ATTENDING A SPECIALISED REGIONAL LIPID CLINIC
Saeed MK*1, Damani R1, Shah J*1, Okonji E1, Rahman F1, Patel P1, Gupta P1  
1Department of Chemical Pathology & Metabolic Diseases, University Hospitals of Leicester, Leicester, UK  

08:00-09:10

Refreshments + networking + exhibition

 

 Medical & Scientific Programme

Health Care Programme

 09:10

Introduction
Mr Stephen BOLEY,  Chairman, HEART UK

Dr Alan REES, Medical Director, HEART UK

09:20-09:45

Scientific aspects of FH genetics

Summary of the mutation spectrum of known genes where mutations cause FH and presentation of newly identified “FH genes”.

 

Prof Steve HUMPHRIES

Emeritus Professor Cardiovascular Genetics

University College London, Institute Cardiovascular Science, London, UK

 

09:45-10:10

Genomics in NHS practice / service

An update on service/national genomics re lipids

 

Dr Maggie WILLIAMS

Consultant Clinical Scientist

Bristol Genetics Laboratory,  Pathology Sciences, Blood Sciences and Bristol Genetics, Southmead Hospital, Bristol, UK

10:10-10:35

New gene targets for dyslipidaemia; realising the promise

Collectively, advances in genetic validation and RNA-based medicines, promise to greatly reduce the failure rate of new therapies; to what extent this promise has been realized will be discussed, with examples of recent progress in the treatment of dyslipidaemias and prevention of CHD.

 

Prof Mike KHAN

Associate Professor of Medicine

University of Warwick and University Hospitals of Coventry and Warwickshire NHS Trust

School of Life Sciences

Coventry, UK

10:35-11:00

Using Computed Tomography to image the coronary arteries

Computed tomography angiography provides not only structural but also functional information about the coronary arteries.

 

Prof Charalambos ANTONIADES

Professor of Cardiovascular Medicine, University of Oxford

Deputy Head, Division of Cardiovascular Medicine

Consultant Cardiologist, Oxford University Hospitals NHSFT

Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford

11:00-11:30

Refreshments + networking + exhibition

11:30-12:45

Medical & Scientific Programme Abstracts of Free Communications 

11:30 – 11:40

1

Coronary calcium score in patients with clinical criteria for familial hypercholesterolaemia
* David AHart T,  Cegla J,  Walji S,  Thompson G, Scott J
Lipid Clinic, Hammersmith Hospital, Imperial NHS Trust, London, UK

 

11:40 – 11:45  Discussion

 

11:45 – 11:55

2

APOLIPOPROTEIN B-100 DECREASES IN ASSOCIATION WITH REDUCTION IN PCSK9 CONCENTRATION IN ACID SPHINGOMYELINASE DEFICIENCY FOLLOWING ENZYME REPLACEMENT THERAPY
Bethanie Garside
1, Yifen Liu2, Sasi Neelamekam1, Jan Hoong Ho1, Shaishav Dhage1, See Kwok1, Simon A. Jones3, Handrean Soran1

1. Cardiovascular Trials Unit, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK

2. Division of Cardiovascular Sciences, Core Technology Facility, University of Manchester, Manchester, UK

3. Manchester Centre for Genomic Medicine, St. Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester, UK

 

11:55 – 12:00  Discussion

 

12:00 – 12:10

3

THE EFFECT OF METABOLIC SURGERY ON LIPOPROTEIN(A), OXIDISED PHOSPHOLIPIDS AND BIOMARKERS OF LIPOPROTEIN OXIDATION

Jan Hoong Ho1,2, Yifen Liu2, Safwaan Adam1,2, Shazli Azmi2, Shaishav Dhage1,2, Akheel Syed3, Basil J Ammori4, Rachelle Donn2, Rayaz A Malik2,5, Xiaohong Yang6, Sotirios Tsimikas6, Handrean Soran1,21Department of Medicine, Manchester University NHS Foundation Trust, Manchester, UK2Lipid Research Group, The University of Manchester, Manchester, UK3Department of Diabetes & Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK4Department of Surgery, Salford Royal NHS Foundation Trust, Salford, UK5Weill Cornell Medicine-Qatar, Doha, Qatar6Department of Cardiovascular Science, University of California, San Diego, USA 

 

12:10 – 12:15  Discussion

 

12:15 – 12:25

4

CHANGES IN SERUM TRIGLYCERIDES ARE ASSOCIATED WITH IMPROVEMENTS IN SMALL FIBRE NEUROPATHY IN OBESE PERSONS FOLLOWING BARIATRIC SURGERY
Adam S 1,2 , Azmi S 1,2 ,  Liu Y 1 ,  Ferdousi M 1,2 ,  Siahmansur T 1 ,  Kalteniece A 1 ,  Marshall A 1,3 , Ho J 1,2 ,  Iqbal Z1,2, Dhage S 1,2 ,  D'Souza Y 2 ,  Natha S 4 ,  Kalra P 1,3 ,  Donn R 1 ,  Syed A 1,3 ,  Ammori B 1,3 , Durrington P 1 ,  Malik R 1,5 ,  Soran H 1,2
1
 University Of Manchester, Manchester Greater Manchester, United Kingdom2 Manchester University Hospitals NHS Foundation Trust, Manchester Greater Manchester, United Kingdom
3 Salford Royal NHS Foundation Trust, Salford Greater Manchester, United Kingdom
4 Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan Lancashire, United Kingdom
5 Weill-Cornell Medicine-Qatar, Doha, Qatar

 

12:25 – 12:30  Discussion

 

12:30 – 12:40

5

MEASURING PCSK9 LEVELS PRIOR TO COMMENCEMENT OF TREATMENT TO INVESTIGATE THE VARIED RESPONSE TO PCSK9 THERAPY
K Peers
*1 H Wiggins 2 S Ramachandran 3,4 A Jones 5

1 Advanced Nurse Practitioner in Department of Clinical Chemistry, Heartlands Hospital, Birmingham, England
2 Senior Clinical Biochemist, Heartlands Hospital, Birmingham, England
3 Researcher in Metabolic Medicine, Warwick University, Midlands, England
4 Professor Metabolic Medicine, Department of Clinical Chemistry, Good Hope Hospital, Birmingham, England 
5 Consultant Physician in Clinical Chemistry, Heartlands Hospital, Birmingham, England 

 

12:40 – 12:45  Discussion

Health Care Programme Abstracts of Free Communications 

 

11:30 – 11:40

1-HC

12 MONTH REVIEW OF LIPID / CHOLESTEROL TESTING THROUGHOUT NORTH WALES (BETSI CADWALADR UNIVERSITY HEALTH BOARD) – AN ADJUNCT FOR FAMILIAL HYPERCHOLESTEROLAEMIA (FH) CASE FINDING
R. Gingell
*1, Y.P. Teoh2, M. Shah2, P. Wainwright2, G. Davies2.1All Wales FH Service, 2Betsi Cadwaladr University Heath Board, North Wales.

 

11:40 – 11:45  Discussion

 

11:45 – 11:55

2-HC

IDENTIFYING 25% OF INDIVIDUALS WITH FH IN THE NEXT 5 YEARS:  IS THIS AN ACHIEVABLE TARGET?
Haralambos K
1*, Whitmore J2, McDowell I1, Humphries S3
1
Cardiff University, 2British Heart Foundation, 3Institute Cardiovascular Sciences, London  

 

11:55 – 12:00  Discussion

 

12:00 – 12:10

3-HC

AGE ADJUSTED WELSH CRITERIA FOR SELECTING PATIENTS FOR FAMILIAL HYPERCHOLESTEROLAEMIA (FH) GENETIC TESTING
Haralambos K
1*, McDowell I1, Gritzmacher L2, Bayly G2, Breen J3, Sherman C4, Cazeaux A4, Ashfield-Watt P1
1
Cardiff University, 2Bristol and Bath FH Service, 3Harefield, London FH Service, 4Wessex FH Service 

 

12:10 – 12:15  Discussion

 

12:15 – 12:25

4-HC

RISK OF CARDIOVASCULAR DISEASE OUTCOMES IN PRIMARY CARE SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA: A COHORT STUDY
Iyen, B1, Qureshi, N1, Kai, J1, Akyea, R.K1, Leonardi-Bee, J2, Roderick, P3, Humphries, S.E*4, Weng, S1
1
Primary Care Stratified Medicine group, Division of Primary care, University of Nottingham, UK
2 Division of Epidemiology and Public Health, University of Nottingham, UK
3 Faculty of Medicine, Primary Care and Population Sciences, University of Southampton, UK
4 Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, UK
 

 

12:25 – 12:30  Discussion

 

12:30 – 12:40

5-HC

VARIANTS OF UNCERTAIN SIGNIFICANCE: HIGHER THAN AVERAGE RESULTS IN YORKSHIRE AND HUMBERSIDE FOR FAMILIAL HYPERCHOLESTEROLAEMIA
J Webster
1*, C Tuson2, C Burton4, K Mitchell1 P Sutton3, R Dunn3, D Chandrajay2, D Narayanan3, M Mansfield4, J Barth4, A Bandyopadhyay2, B Powers, K Haralambos5
1Calderdale and Huddersfield NHS Trust, England
2York Teaching Hospitals NHS Foundation Trust, England
3Hull Teaching Hospitals NHS Trust, England
4Leeds Teaching Hospitals NHS Trust, England
5Cardiff and Vale University Hospitals Board, Wales
 

 

12:40 – 12:45  Discussion

12:45-14:00

Lunch + networking + exhibition

12:45-14:00

Simon Broome committee meeting

Host: Nigel CAPPS

14:00-15:30

Clinical Lipidology Live!

Interactive case study session in a panel format with perspectives from lipidology and cardiology.
Facilitator: Dr Dev DATTA, Cardiff, Wales, UK

15:30-16:15

 Refreshments + networking + exhibition

16:15-17:15

MYANT LECTURE:

Causes and consequences of human obesity

Prof Sir Stephen O’RAHILLY

Professor of Clinical Biochemistry and Medicine and Director
Metabolic Research Laboratories, University of Cambridge, UK

17:15-17:45

Networking opportunity

17:15-18:15

HEART UK Health Care committee meeting

Host: Michaela NUTTALL

17:45

Conference close - day two

19:00-19:45

Conference pre dinner drinks

19:45-24:00

Bollywood themed conference dinner and dance

Friday 5 July 2019

08:00

Registration opens

08:00-09:00

Apheresis Working group committee meeting

Host: Dev DATTA

08:30-09:30

Refreshments + networking + exhibition

 

 Medical & Scientific Programme

Health Care Programme

 09:30-09:40

Opening remarks
Dr Alan REES, Medical Director, HEART UK

 09:40-10:20

Inherited Lipoprotein Disorders: Update on Paediatric Familial Hypercholesterolaemia and overview of inherited disorders of triglyceride metabolism in children

 

Dr Uma RAMASWAMI

Consultant Paediatrician in inherited metabolic disorders
Royal Free Hospital, London, UK

10:20-10:45

Refreshments + networking + exhibition

 

Medical & Scientific Programme 

Hot topics

Health Care Programme 

10:45-11:15

10:45-11:05

Volanesorsen Effectively Reduces Triglycerides in Familial Chylomicronemia Syndrome: The APPROACH Study

Dr Handrean SORAN

Consultant Physician & Endocrinologist, Manchester University Hospital, UK

10:45-11:15

Dementia Prevention - the basics

Dementia is the most feared condition of the over 55s, freshen up on the basics for to improve prevention.

 

Ms Michaela NUTTALL

Cardiovascular nurse specialist
Bromley, UK

11:15-11:30

Transfer to main meeting space

11:30-12:00

The ASCEND study and the role of aspirin in the primary prevention of cardiovascular disease and cancer

Recent trials, including the ASCEND study of 15,480 people with diabetes in the UK, have clarified the role of aspirin for primary prevention of cardiovascular disease and shed some light on the debate about aspirin use and cancer risk

 

Dr Marion MAFHAM

Senior Clinical Fellow
CTSU, Nuffield Department of Population Health, University of Oxford, Oxford, UK

 12:00-12:10

Presentation of prizes and awards

Dr Alan REES

Medical Director, HEART UK

12:15-12:55

SPONSORED SYMPOSIUM 3:

Identifying Familial Chylomicronaemia Syndrome: Clinical Manifestations and Genetic Confirmation

 

                                                                                                                                                              

 

12:15–12:20    

Welcome and introduction                                

Dr Mathangi BALASUBRAMANI

Consultant in Chemical Pathology

Department of Chemical Pathology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK

 

12:20–12:35 

Focus on familial chylomicronaemia syndrome (FCS)

Dr Mathangi BALASUBRAMANI



12:35–12:50 

The future of genetic testing for the diagnosis of FCS in the UK    

Dr Maggie WILLIAMS

Consultant Clinical Scientist

Bristol Genetics Laboratory,  Pathology Sciences, Blood Sciences and Bristol Genetics, Southmead Hospital, Bristol, UK

 

12:50–12:55    

Q&A                                                                   

Chaired by Dr Maggie Williams

 

12:55

Conference ends + delegate departure

 

Register now